Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD

描述(由申请者提供)：目前对下肢外周动脉疾病(PAD)患者的治疗选择有限，适当地重点放在心血管危险因素的修改上，以预防这些高危患者的冠状动脉或脑血管事件。不幸的是，关于肢体相关的结果，到目前为止，还没有令人信服的药物疗法被证明可以预防无症状个体的临床显性疾病，而在有症状的患者中，改善跛行、改善身体功能或防止局部进展为肢体威胁疾病的药物选择太少。这项辅助研究建议将把目前正在心血管炎症减少试验(CIRT)中测试的动脉粥样硬化血栓的炎症假说扩展到包括下肢外周动脉粥样硬化，这种疾病经常与冠状动脉疾病并存，并具有许多先前的危险因素，包括2型糖尿病(T2D)、代谢综合征(METS)和亚临床炎症。CIRT是一项由NHLBI资助的多中心临床试验(U01 HL101422和U01 HL101389)，将在2至4年(平均3年)的随访期内，随机将7000名有心肌梗死(MI)和T2D和/或MET的受试者分配到低剂量甲氨蝶呤(LDM；目标剂量为每周15-20毫克)加常规护理或安慰剂+常规护理的组。参与者将从美国和加拿大的大约350到400个临床地点招募。主要终点是非致命性心肌梗死、中风和心血管死亡。虽然PAD是试验的第三个终点，但终点判定和用于诊断和监测疾病的踝臂指数(ABI)测量目前不由该试验资助。我们建议在随机、双盲、安慰剂对照的设置中评估LDM是否将1)通过ABI的变化来评估PAD的进展，2)延缓通过基于问卷和基于绩效的身体功能测量的变化并与ABI的变化相关的功能衰退，以及3)减少PAD事件的发生，包括确认的间歇性跛行、严重的肢体缺血、下肢血管重建、截肢或ABI&lt；的新发生。总之，我们相信，父母CIRT试验的研究基础设施提供了一个独特且极具成本效益的机会，可以及时回答有关抗炎治疗对预防和治疗下肢PAD的潜在好处的重要和及时的问题。我们寻求资金支持终点验证，并为CIRT招募地点提供用于确定ABI的多普勒ABI设备，从而有效地将PAD提升到试验的判定终点，现在纳入了PAD研究社区广泛接受的诊断模式。为了获得足够大的样本量以实现我们的科学目标，这项自然延伸的母项研究必须与2013年4月开始的整个CIRT招募工作同时进行。

DESCRIPTION (provided by applicant): Current treatment options for patients with lower extremity peripheral artery disease (PAD) are limited with appropriately heavy emphasis placed on cardiovascular risk factor modification to prevent coronary or cerebrovascular events in these high-risk patients. Unfortunately, with regard to limb-related outcomes, to date, no pharmacologic therapy has convincingly been shown to prevent clinically overt disease in asymptomatic individuals and among symptomatic patients, too few medical options exist to ameliorate claudication, improve physical function, or prevent local progression to limb threatening disease. This ancillary study proposal will extend the inflammatory hypothesis of atherothrombosis currently being tested in the Cardiovascular Inflammation Reduction Trial (CIRT) to encompass lower extremity peripheral atherosclerosis, a disease which frequently co-exists with coronary disease and shares many antecedent risk factors including type 2 diabetes (T2D), metabolic syndrome (MetS) and subclinical inflammation. CIRT is an NHLBI funded multicenter clinical trial (U01 HL101422 and U01 HL101389) that will randomly allocate 7,000 subjects with prior myocardial infarction (MI) and either T2D and/or MetS to low dose methotrexate (LDM; target dose 15 to 20 mg per week) plus usual care or placebo plus usual care over a follow-up period of 2 to 4 years (average 3 years). Participants will be recruited from roughly 350 to 400 clinical sites in the United States and Canada. The primary endpoint is nonfatal MI, stroke, and cardiovascular death. While PAD is a tertiary endpoint of the trial, endpoint adjudication and ankle-brachial index (ABI) measurement for diagnosis and monitoring of disease are currently not funded by the trial. We propose to evaluate in a randomized, double-blind, placebo-controlled setting whether LDM will 1) reduce PAD progression as assessed by change in ABI, 2) retard functional decline as measured by change in both questionnaire-based and performance- based physical function measures and correlated with change in ABI, and 3) reduce the occurrence of PAD events including confirmed intermittent claudication, critical limb ischemia, lower extremity revascularization, amputation, or new occurrence of ABI < 0.9. In summary, we believe that the research infrastructure of the parent CIRT trial offers a unique and extremely cost-effective opportunity to answer important and timely questions about the potential benefits of anti-inflammatory therapy for the prevention and treatment of lower extremity PAD. We seek funds to support endpoint validation and to provide CIRT recruiting sites with Doppler ABI equipment for ascertainment of the ABI thus effectively elevating PAD to an adjudicated endpoint of the trial and now incorporating a diagnostic modality widely acceptable to the PAD research community. In order to achieve a sufficiently large sample size to address our scientific goals, this natural extension of the parent study must be undertaken in parallel with overall CIRT recruitment which began in April 2013.